MARY MARTIN: Open Payments
NPI 1477863082 · RIVERHEAD, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,119 in 136 payments from 14 companies in 2025. Trend: 2023 $2,312 · 2024 $2,119 · 2025 $3,119
Food & beverage: $3,119
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 36 | $642 |
| Alkermes, Inc. | 14 | $414 |
| Axsome Therapeutics, Inc. | 12 | $407 |
| ABBVIE INC. | 13 | $342 |
| Neurocrine BioSciences, Inc. | 12 | $260 |
| Lundbeck LLC | 10 | $243 |
| E.R. Squibb & Sons, L.L.C. | 7 | $174 |
| Corium, LLC | 8 | $143 |
| Otsuka America Pharmaceutical, Inc. | 6 | $121 |
| Collegium Pharmaceutical, Inc. | 6 | $117 |
Products named: CAPLYTA, Auvelity, ARISTADA, REXULTI, VRAYLAR, INGREZZA, COBENFY, Azstarys.
Industry payments across NY — which companies pay providers there.
